GeoVax Labs (GOVX) Change in Receivables (2010 - 2025)
GeoVax Labs (GOVX) posted quarterly Change in Receivables of -$532771.0 for Q3 2025, down 315.79% year-over-year from $246897.0 in Q3 2024, and up 44.78% quarter-over-quarter from -$964774.0 in Q2 2025.
GeoVax Labs (GOVX) Change in Receivables (2010 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Change in Receivables for 15 consecutive years, with -$532771.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Receivables fell 315.79% year-over-year to -$532771.0; the TTM figure through Dec 2025 stood at -$659409.0 (down 200.0% YoY), while the FY2025 annual figure was -$659409.0, down 200.0% from the prior year.
- Change in Receivables advanced to -$532771.0 in Q3 2025 per GOVX's latest filing, from -$964774.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $838136.0 in Q1 2025 and bottomed at -$964774.0 in Q2 2025.
- Historically, Change in Receivables has averaged -$18266.3 across 4 years, with a median of $49763.0 in 2021.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 127.66% — and 2025, when it tumbled 420.87%.
- GeoVax Labs' Change in Receivables stood at $49006.0 in 2021, then tumbled by 303.09% to -$99526.0 in 2022, then jumped by 212.37% to $111835.0 in 2024, then slumped by 576.39% to -$532771.0 in 2025.
- Business Quant data shows GOVX's Change in Receivables at -$532771.0 in Q3 2025, -$964774.0 in Q2 2025, and $838136.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -532,771.00 |
| Sep 30, 2025 | -532,771.00 |
| Jun 30, 2025 | -964,774.00 |
| Jun 30, 2025 | -964,774.00 |
| Mar 31, 2025 | 838,136.00 |
| Mar 31, 2025 | 838,136.00 |
| Dec 31, 2024 | 111,835.00 |
| Dec 31, 2024 | 111,835.00 |
| Sep 30, 2024 | 246,897.00 |
| Sep 30, 2024 | 246,897.00 |
| Jun 30, 2024 | 300,677.00 |
| Jun 30, 2024 | 300,677.00 |
| Jun 30, 2022 | -99,526.00 |
| Jun 30, 2022 | -99,526.00 |
| Mar 31, 2022 | 50,520.00 |
| Mar 31, 2022 | 50,520.00 |
| Dec 31, 2021 | 49,006.00 |
| Dec 31, 2021 | 49,006.00 |
| Mar 31, 2021 | -182,663.00 |
| Mar 31, 2021 | -182,663.00 |